Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice

Thrombosis and Haemostasis

Volumn 111, Issue 2, 2013, Pages 308-322

  Nencioni, Alessio ^a   da Silva, Rafaela F ^b,c   Fraga Silva, Rodrigo A ^b,c   Steffens, Sabine ^d   Fabre, Mathias ^e   Bauer, Inga ^a   Caffa, Irene ^a   Magnone, Mirko ^f   Sociali, Giovanna ^f   Quercioli, Alessandra ^e   Pelli, Graziano ^e   Lenglet, Sébastien ^e   Galan, Katia ^e   Burger, Fabienne ^e   Calvo, Sara Vázquez ^e   Bertolotto, Maria ^a   Bruzzone, Santina ^f   Ballestrero, Alberto ^a   Patrone, Franco ^a   Dallegri, Franco ^a   Santos, Robson A S ^c   Stergiopulos, Nikolaos ^b   Mach, François ^e   Vuilleumier, Nicolas ^g   Montecucco, Fabrizio ^a,e   more..

^a UNIVERSITY OF GENOA   (Italy)

^b EPFL   (Switzerland)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^e UNIVERSITY OF GENEVA   (Switzerland)

^f UNIVERSITY OF GENOA   (Italy)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Atherosclerosis; Carotid artery; Inflammation

Indexed keywords

COLLAGEN; CXCL1 CHEMOKINE; DAPORINAD; GELATINASE B; NEUTROPHIL COLLAGENASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TRANSCRIPTION FACTOR RELA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ATHEROSCLEROSIS; CELL CULTURE; CELL ISOLATION; CELL VIABILITY; CONTROLLED STUDY; DEGRANULATION; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NEUTROPHIL CHEMOTAXIS; NICK END LABELING; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ATHEROSCLEROSIS; CAROTID ARTERY; INFLAMMATION;

ACRYLAMIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CELLS, CULTURED; CHEMOKINE CXCL1; COLLAGEN; CYTOKINES; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHIL INFILTRATION; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIPERIDINES; PLAQUE, ATHEROSCLEROTIC; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTOR RELA;

EID: 84893186412     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th13-07-0531     Document Type: Article

References (36)

1. Van Gool F, Gallí M, Gueydan C, et al. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat Med 2009; 15: 206-210.
2. Busso N, Karababa M, Nobile M, et al. Pharmacological inhibition of nicotina-mide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 2008; 3: e2267.
3. Bruzzone S, Fruscione F, Morando S, et al. Catastrophic NAD+ depletion in activated T lymphocytes through NAMPT inhibition reduces demyelination and disability in EAE. PLoS One 2009; 4: e7897.
4. Montecucco F, Bauer I, Braunersreuther V, et al. Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid Redox Signal 2013; 18: 630-641.
5. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003; 63: 7436-7442.
6. Moschen AR, Gerner R, Schroll A, Fritz T, Kaser A, Tilg H. A key role for Pre-B cell colony-enhancing factor in experimental hepatitis. Hepatology 2011; 54: 675-686.
7. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410-1422.
8. Koenen RR, Weber C. Chemokines: established and novel targets in atherosclerosis. EMBO Mol Med 2011; 3: 713-725.
9. Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ Res 2012; 110: 875-888.
10. Montecucco F, Di Marzo V, da Silva RF, et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J 2012; 33: 846-856.
11. Montecucco F, Lenglet S, Gayet-Ageron A, et al. Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischaemic stroke. Stroke 2010; 41: 1394-1404.
12. Copin JC, da Silva RF, Fraga-Silva RA, et al. Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischaemic stroke, but not brain injury in mice. Cereb Blood Flow Metab 2013; 33: 490-498.
13. Koenen RR, Weber C. Manipulating the chemokine system: therapeutic perspectives for atherosclerosis. Curr Opin Investig Drugs 2010; 11: 265-272.
14. Koenen RR, Weber C. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov 2010; 9: 141-153.
15. Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in mac-rophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilisation. Circulation 2007; 115: 972-980.
16. Cheng C, Tempel D, van Haperen R, et al. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation 2006; 113: 2744-2753.
17. Lenglet S, Thomas A, Soehnlein O, et al. Fatty acid amide hydrolase deficiency enhances intraplaque neutrophil recruitment in atherosclerotic mice. Arte-rioscler Thromb Vasc Biol 2013; 33: 215-223.
18. van Leeuwen M, Gijbels MJ, Duijvestijn A, et al. Accumulation of myeloperox-idase-positive neutrophils in atherosclerotic lesions in LDLR-/- mice. Arte-rioscler Thromb Vasc Biol 2008; 28: 84-89.
19. Polykratis A, van Loo G, Xanthoulea S, Hellmich M, Pasparakis M. Conditional targeting of tumor necrosis factor receptor-associated factor 6 reveals opposing functions of Toll-like receptor signalling in endothelial and myeloid cells in a mouse model of atherosclerosis. Circulation 2012; 126: 1739-1751.
20. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112.
21. Graeff R, Lee HC. A novel cycling assay for cellular cADP-ribose with nanomo-lar sensitivity. Biochem J 2002; 361: 379-384.
22. Skokowa J, Lan D, Thakur BK, et al. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat Med 2009; 15: 151-158.
23. Quercioli A, Mach F, Bertolotto M, et al. Receptor activator of NF- & B ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thromb Haemost 2012; 107: 124-139.
24. Shattuck RL, Wood LD, Jaffe GJ, Richmond A. MGSA/GRO transcription is differentially regulated in normal retinal pigment epithelial and melanoma cells. Mol Cell Biol 1994; 14: 791-802.
25. Wood LD, Farmer AA, Richmond A. HMGI(Y) and Sp1 in addition to NF-kappa B regulate transcription of the MGSA/GRO alpha gene. Nucleic Acids Res 1995; 23: 4210-4219.
26. Ohtsuka T, Kubota A, Hirano T, et al. Glucocorticoid-mediated gene suppression of rat cytokine-induced neutrophil chemoattractant CINC/gro, a member of the interleukin-8 family, through impairment of NF-kappa B activation. J Biol Chem 1996; 271: 1651-1659.
27. Pierce J W, Schoenleber R, Jesmok G, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997; 272: 21096-21103.
28. Olsen LS, Hjarnaa PJ, Latini S, et al. Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity. Int J Cancer 2004; 111: 198-205.
29. Hassan SB, Lövborg H, Lindhagen E, et al. CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome. Anticancer Res 2006; 26: 4431-4436.
30. Esposito E, Impellizzeri D, Mazzon E, et al. The NAMPT inhibitor FK866 reverts the damage in spinal cord injury. J Neuroinflammation 2012; 9: 66.
31. Soehnlein O, Drechsler M, Döring Y, et al. Distinct functions of chemokine receptor axes in the atherogenic mobilisation and recruitment of classical mono-cytes. EMBO Mol Med 2013; 5: 471-481.
32. Boisvert WA, Rose DM, Johnson KA, et al. Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am J Pathol 2006; 168: 1385-1395.
33. Montecucco F, Lenglet S, Braunersreuther V, et al. Single administration of the CXC chemokine-binding protein Evasin-3 during ischaemia prevents myo-cardial reperfusion injury in mice. Arterioscler Thromb Vasc Biol 2010; 30: 1371-1377.
34. Wan W, Murphy PM. Regulation of atherogenesis by chemokines and chemo-kine receptors. Arch Immunol Ther Exp 2013; 61: 1-14.
35. Drechsler M, Megens RT, van Zandvoort M, et al. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010; 122: 1837-1845.
36. Shimomura I, Shimano H, Korn BS, et al. Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsatu-rated fatty acid biosynthesis in transgenic mouse liver. J Biol Chem 1998; 273: 35299-35306.